KR102248449B9 - 신규한 클로린 e6-커큐민 유도체, 그 제조 방법 및 그것을 함유하는 암 치료용 약학 조성물 - Google Patents

신규한 클로린 e6-커큐민 유도체, 그 제조 방법 및 그것을 함유하는 암 치료용 약학 조성물

Info

Publication number
KR102248449B9
KR102248449B9 KR1020170080023A KR20170080023A KR102248449B9 KR 102248449 B9 KR102248449 B9 KR 102248449B9 KR 1020170080023 A KR1020170080023 A KR 1020170080023A KR 20170080023 A KR20170080023 A KR 20170080023A KR 102248449 B9 KR102248449 B9 KR 102248449B9
Authority
KR
South Korea
Prior art keywords
cancer
treatment
pharmaceutical composition
composition containing
same
Prior art date
Application number
KR1020170080023A
Other languages
English (en)
Other versions
KR20190000971A (ko
KR102248449B1 (ko
Inventor
김용완
에스 얄데 시바쿠마르
손광희
이환석
Original Assignee
동성제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동성제약주식회사 filed Critical 동성제약주식회사
Priority to KR1020170080023A priority Critical patent/KR102248449B1/ko
Priority to PCT/KR2018/007124 priority patent/WO2018236193A1/en
Publication of KR20190000971A publication Critical patent/KR20190000971A/ko
Priority to US16/724,703 priority patent/US20200172549A1/en
Application granted granted Critical
Publication of KR102248449B1 publication Critical patent/KR102248449B1/ko
Publication of KR102248449B9 publication Critical patent/KR102248449B9/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020170080023A 2017-06-23 2017-06-23 신규한 클로린 e6-커큐민 유도체, 그 제조 방법 및 그것을 함유하는 암 치료용 약학 조성물 KR102248449B1 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020170080023A KR102248449B1 (ko) 2017-06-23 2017-06-23 신규한 클로린 e6-커큐민 유도체, 그 제조 방법 및 그것을 함유하는 암 치료용 약학 조성물
PCT/KR2018/007124 WO2018236193A1 (en) 2017-06-23 2018-06-22 NOVEL CHLORIN E6-CURCUMINE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR THE TREATMENT OF CANCER
US16/724,703 US20200172549A1 (en) 2017-06-23 2019-12-23 Novel chlorin e6-curcumin derivatives, preparation method thereof, and pharmaceutical composition containing the same for treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170080023A KR102248449B1 (ko) 2017-06-23 2017-06-23 신규한 클로린 e6-커큐민 유도체, 그 제조 방법 및 그것을 함유하는 암 치료용 약학 조성물

Publications (3)

Publication Number Publication Date
KR20190000971A KR20190000971A (ko) 2019-01-04
KR102248449B1 KR102248449B1 (ko) 2021-05-06
KR102248449B9 true KR102248449B9 (ko) 2022-03-15

Family

ID=64736035

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170080023A KR102248449B1 (ko) 2017-06-23 2017-06-23 신규한 클로린 e6-커큐민 유도체, 그 제조 방법 및 그것을 함유하는 암 치료용 약학 조성물

Country Status (3)

Country Link
US (1) US20200172549A1 (ko)
KR (1) KR102248449B1 (ko)
WO (1) WO2018236193A1 (ko)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101344303B1 (ko) * 2011-10-07 2013-12-24 동성제약주식회사 표적 치료에 관한 종양에 선택성이 있는 콘쥬게이트
CN103224499B (zh) * 2013-04-07 2015-06-03 华南理工大学 具有光敏活性的脱镁叶绿酸姜黄素酯及其制备方法与应用
KR101582306B1 (ko) 2013-04-22 2016-01-05 애니젠 주식회사 커큐민에 비하여 용해도가 향상된 커큐민―펩타이드 복합체 및 이의 제조방법

Also Published As

Publication number Publication date
US20200172549A1 (en) 2020-06-04
KR20190000971A (ko) 2019-01-04
KR102248449B1 (ko) 2021-05-06
WO2018236193A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3490581A4 (en) NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR TREATMENT OF CANCER
PL3616720T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu
EP3533466A4 (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
IL263793A (en) Compounds and preparations for the treatment of cancer
IL261278A (en) Pharmaceutical compositions for the treatment of cancer
EP3518918A4 (en) METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
IL265292A (en) Medicinal compound and method for treating non-alcoholic fatty liver disease
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
IL260890A (en) Method and pharmaceutical composition for the treatment of neurodegeneration
HK1217303A1 (zh) 種治療白血病的藥物組合物及其製備方法
IL274008A (en) Anti-MSLN antibody and a pharmaceutical preparation containing it for the treatment of cancer
EP3468540A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
EP3400942A4 (en) USE OF QUINOLINE DERIVATIVES FOR THE TREATMENT OF SOPHAGE CANCER AND METHOD OF TREATMENT, PHARMACEUTICAL COMPOSITION AND KIT THEREOF
IL265824A (en) Methods and pharmaceutical compositions for the treatment of kidney cancer
EP3576761A4 (en) HERBO-MINERAL FORMULATION FOR THE TREATMENT OF CANCER AND RELATED PREPARATION PROCESS
EP3563856A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND USE THEREOF
EP3525787A4 (en) TREATMENT METHODS AND PHARMACEUTICAL COMPOSITIONS USING BCN057 OR BCN512
EP3406626A4 (en) PEPTIDE FOR CANCER TREATMENT, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
KR102248449B9 (ko) 신규한 클로린 e6-커큐민 유도체, 그 제조 방법 및 그것을 함유하는 암 치료용 약학 조성물
GB201718927D0 (en) Pharmaceutical composition suitable for intestinal cancer treatment and/or prevention

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
X091 Application refused [patent]
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]